Real-world experience with 11C-methionine positron emission tomography in the management of acromegaly.
Linus HaberboschJames MacFarlaneOlympia KoulouriDaniel GillettAndrew S PowlsonSue OddyDavid J HalsallKevin A HuynhJonathan JonesHeok K CheowJoachim SprangerKnut MaiChristian J StrasburgerRichard J MannionMark GurnellPublished in: European journal of endocrinology (2024)
In patients with persistent/recurrent acromegaly or occult tumors, Met-PET can facilitate further targeted intervention (surgery/radiosurgery). This led to complete remission in most cases (24/33) or significant improvement with comparatively low risk of complications. L-[methyl-11C]-methionine-positron emission tomography should therefore be considered in all patients who are potential candidates for further surgical intervention but present no clear target on MRI.
Keyphrases
- positron emission tomography
- computed tomography
- pet ct
- randomized controlled trial
- pet imaging
- end stage renal disease
- magnetic resonance imaging
- minimally invasive
- contrast enhanced
- ejection fraction
- peritoneal dialysis
- coronary artery bypass
- prognostic factors
- small cell lung cancer
- tyrosine kinase
- risk factors
- magnetic resonance
- risk assessment
- brain metastases
- drug delivery
- cancer therapy
- disease activity
- growth hormone
- diffusion weighted imaging
- systemic lupus erythematosus